Федон Линдберг - X-фактор здорового веса. Как добиться естественной стройности, позаботившись о кишечнике

165. Chatterjee S et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol.2007 Apr;102(4):837–841

166. DiBaise JK. Nutritional consequences of small intestinal bacterial overgrowth. PracGastroenterol. 2008;69:15–28

167. Pimentel M. A New IBS Solution. Sherman Oaks, CA: Health Point Press; 2006

168. Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (NY). 2009 Jun;5(6):435–42

169. Husebye, E. «Bakteriell overvekst i klinisk perspektiv». http://gastroenterologen.no/2012/05/bakteriell-overvekst-i-klinisk-perspektiv/

170. Johnson, S. «Lav FODMAP diet for deg med irritabel tarm». http://ernaeringsportalen.no/2014/lav-fodmap-for-deg-med-irritabel-tarm/

171. Ardatskaia MD, Loginov VA, Minushkin ON. Syndrome of bacterial overgrowth in patients with reduced stomach acid secretion: some aspects of the diagnosis. Eksp Klin Gastroenterol. 2014;(12):30–6

172. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013 May;11(5):483–90

173. Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin

174. GE. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014 May;3(3):16–24

175. Biagi, E. et al. Ageing and gut microbes: Perspectives for health maintenance and longevity: http://www.sciencedirect.com/science/article/pii/S1043661812001922

176. Mitsuoka T. Intestinal flora and human health. Asia Pac J Clin Nutr. 1996 Mar;5(1):2–9

177. Woodmansey EJ. Intestinal bacteria and ageing. J Appl Microbiol. 2007 May;102(5):1178–86. Review

178. Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev. 2010 Apr;9(2):107–16. doi: 10.1016/j.arr.2009.10.004. Epub 2009 Oct 27. Review

179. He F, Ouwehand AC, Isolauri E, Hosoda M, Benno Y, Salminen S. Differences in composition and mucosal adhesion of bifidobacteria isolated from healthy adults and healthy seniors. Curr Microbiol. 2001 Nov;43(5):351–4

180. Weight-control Information Network. Overweight and Obesity Statistics. Bethesda, MD: National Institute of Diabetes and Digestive Kidney Diseases; October 2012

181. Ogden CL, Carroll MD. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960–1962 through 2007–2008. Atlanta, GA: National Center for Health Statistics, Centers for Disease Control and Prevention; June 2010

182. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among U.S. adults, 1999–2010. JAMA. 2012 Feb;307(5):491–497

183. Wilding BC, Curtis K, Welker-Hood K. Hazardous Chemicals in Health Care: A Snapshot of Chemicals in Doctors and Nurses. Washington, DC: Physicians for Social Responsibility; 2009

184. Centers for Disease Control and Prevention, National Center for Environmental Health. Fourth National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: Centers for Disease Control and Prevention; 2009

185. Committee on National Monitoring of Human Tissues, Board on Environmental Studies and Toxicology, National Research Council. Monitoring Human Tissues for Toxic Substances. Washington, DC: The National Academies Press, 1991

186. Kutz FW, Strassman SC, Sperling JF. Survey of selected organochlorine pesticides in the general population of the United States: Fiscal years 1970–1975. Ann N Y Acad Sci.1979 May 31;320:60–68

187. Strassman SC, Kutz FW. Trends of organochlorine pesticide residues in human tissue. In: Khan MAQ, Stanton RH eds. Toxicology of Halogenated Hydrocarbons: Health & Ecological Effects. New York: Pergamon Press; 1981

188. Environmental Working Group. Body Burden – The Pollution in Newborns. Washington, DC: Environmental Working Group; July 2005

189. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002 Apr;8(2):185–192

190. Blumberg B, Grün F. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. Endocrinology 2006 Jun;147(6 Suppl):S50–S55

191. Heindel JJ. Endocrine disruptors and the obesity epidemic. Toxicol Sci. 2003 Dec;76(2):247–249

192. Holtcamp W. Obesogens: Environmental link to obesity? Environ Health Perspect. 2012 Feb;120(2):a62–a68

193. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. Perinatal exposure to environmental estrogens and the development of obesity. Mol Nutr Food Res. 2007;51:912–917

194. Toschke AM, Koletzko B, Slikker Jr W, Hermann M, von Kries R. Childhood obesity is associated with maternal smoking in pregnancy. Eur J Pediatr. 161:445–448.

195. Environmental Working Group. Body burden, the pollution in newborns. http://www.ewg.org/research/body-burden-pollution-newborns

196. Fakta om glyfosat. Mattilsynet. http://www.mattilsynet.no/planter_og_dyrking/plantevernmidler/godkjenning_av_plantevernmidler/fakta_om_glyfosat.3100/BINARY/Fakta%20om%20glyfosat

197. Duke SO, Powles SB. Glyphosate: a once-in-a-century herbicide. Pest Manag Sci. 2008 Apr;64(4):319–25. Review

198. Samsel A, Seneff S. Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies. Surg Neurol Int. 2015 Mar 24;6:45

199. Samsel A, Seneff S. Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance. Interdiscip Toxicol. 2013 Dec;6(4): 159–84

200. Krüger M, Shehata AA, Schrödl W, Rodloff A. Glyphosate suppresses the antagonistic effect of Enterococcus spp. on Clostridium botulinum. Anaerobe. 2013 Apr;20:74–8

201. Shehata AA, Schrödl W, Aldin AA, Hafez HM, Krüger M. The effect of glyphosate on potential pathogens and beneficial members of poultry microbiota in vitro. Curr Microbiol. 2013 Apr;66(4):350–8

202. Summers AO, Wireman J, Vimy MJ, Lorscheider FL, Marshall B, Levy SB, Bennett S, Billard L. Mercury released from dental “silver” fillings provokes an increase in mercury-and antibiotic-resistant bacteria in oral and intestinal floras of primates. Antimicrob Agents Chemother. 1993 Apr;37(4):825–34

203. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut Oct 2004;53(10):1459–1464

204. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The Fecal Microbial-Population in the Irritable Bowel Syndrome. Microbiologica 1982;5(3):185–194

205. Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. Oct 2012;46 Suppl:S52–55

206. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and non-allergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. Jul 2012;5(4):261–268

207. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. Mar 2011;106(3):508–514; quiz 515

208. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. May 1999;94(5):1327–1331

209. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. Dec 2004a;10(6):1015–1018